4 completed, 1 active not recruiting, 1 not yet recruiting. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 4, Active not recruiting 1, Not yet recruiting 1 |
Follow Adherence, Medication: new trials by email Literature Review of Adherence, Medication trials Research Report on Adherence, Medication
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer Adherence package consisting of additional education and adherence reminders - Breast Cancer, Adherence, Medication | Phase 4 | Not yet recruiting | Institute of Oncology Ljubljana | 90 | 2026-09-01 | 2026-06-05 |
| Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery Apixaban 2.5 milligram - Neoplasms Malignant, Surgery | Phase 4 | Completed | McMaster University | 53 | 2021-02-22 | 2022-04-22 |
| Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) Elexacaftor/Tezacaftor/Ivacaftor - Cystic Fibrosis, Cystic Fibrosis Liver Disease | Phase 4 | Active not recruiting | Royal College of Surgeons, Ireland | 206 | 2020-09-03 | 2026-09-09 |
| DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men Emtricitabine / Tenofovir Disoproxil Oral Tablet, DOT Diary mobile app - Adherence, Medication, Risk Behavior | Phase 4 | Completed | Public Health Foundation Enterprises, Inc. | 100 | 2019-02-01 | 2025-07-03 |
| Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use Digital pill, Truvada - HIV/AIDS, Substance Use Disorders | Phase 4 | Completed | Brigham and Women's Hospital | 16 | 2018-10-01 | 2022-12-22 |
| DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence Emtricitabine / Tenofovir Disoproxil Oral Tablet, DOT Diary mobile app - Adherence, Medication, Risk Behavior | Phase 4 | Completed | Public Health Foundation Enterprises, Inc. | 20 | 2018-02-28 | 2021-10-27 |
Medication Adherence (6) · Risk-Taking (2) · Acquired Immunodeficiency Syndrome (1) · Breast Neoplasms (1) · Cystic Fibrosis (1) · Neoplasms (1) · Substance-Related Disorders (1) · Venous Thromboembolism (1)
Behavior (6) · Health Behavior (6) · Patient Acceptance of Health Care (6) · Patient Compliance (6) · Treatment Adherence and Compliance (6) · Blood-Borne Infections (1) · Breast Diseases (1) · Cardiovascular Diseases (1) · Chemically-Induced Disorders (1) · Communicable Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Embolism and Thrombosis (1) · Genetic Diseases, Inborn (1) · Genital Diseases (1)
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (3) · elexacaftor, ivacaftor, tezacaftor drug combination (1)
Public Health Foundation Enterprises, Inc. (2) · Brigham and Women's Hospital (1) · Institute of Oncology Ljubljana (1) · McMaster University (1) · Royal College of Surgeons, Ireland (1)
United States (3) · Canada (1) · Ireland (1) · Slovenia (1) · United Kingdom (1)
Susan Buchbinder, MD (2) · Sam Schulman, MD, PhD (1)
PMID 33044687, PMID 34753871, PMID 35089449, PMID 35362102, PMID 37703083, PMID 39222964
R01MH109320 (2)